{
    "nctId": "NCT00588640",
    "briefTitle": "Study of D-Methadone in Patients With Chronic Pain",
    "officialTitle": "A Phase I/II Study of D-Methadone in Patients With Chronic Pain",
    "overallStatus": "COMPLETED",
    "conditions": "Pain, Bladder Cancer, Breast Cancer, CNS Cancer, Colon Cancer, Esophageal Cancer, Pancreatic Cancer, Prostate Cancer, Uterine Cancer, Head and Neck Cancer, Eye Cancer, Otorhinolaryngologic Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 10,
    "primaryOutcomeMeasure": "Number Who Reached a Safe Dose",
    "eligibilityCriteria": "Inclusion Criteria:\n\nPhase I and Phase II portions of the study:\n\n* 18 years of age or older\n* Chronic pain with average 24 hour intensity rated at least 3 on a verbal numerical scale from 0-10 during the 24 hours prior to study entry.\n* Give informed consent to participate in this study.\n* Karnofsky Performance Score (KPS) \\>= to 80\n* Negative urine pregnancy test, verified by the study nurse, at study entry (for women of child-bearing potential). Patients must also use a medically approved contraceptive method during the study period.\n\nPhase I only:\n\n* Responsible companion living with patient during study.\n\nPhase II only:\n\n* Group 1 -- Patients must be taking chronic opioid therapy (long acting morphine, long acting oxycodone, transdermal fentanyl) at a stable dose for a minimum of four days. The dose of as needed short acting opioid does not need to be stable.\n* Group 2 -- Patients must not be receiving opioids and must have cancer related neuropathic pain secondary to post-chemotherapy peripheral neuropathy, post-radiation and/or post surgical plexopathy, radiculopathy or neuropathy, or post- herpetic neuralgia.\n\nExclusion Criteria:\n\nPhase I and Phase II:\n\n* Known hypersensitivity to methadone\n* Patient taking methadone or with a history of methadone treatment within one month of study enrollment.\n* Patient that requires changes in the dose of one of the following medications within 2 weeks of study enrollment:\n\n  * Abacavir,\n  * Benzodiazepines,\n  * Carbamazepine,\n  * Efavirenz,\n  * Fluconazole,\n  * Fluvoxamine,\n  * FOS amprenavir,\n  * Fosphenytoin,\n  * Naltrexone,\n  * Nelfinavir,\n  * Nevirapine,\n  * Phenytoin,\n  * Rifampin,\n  * Rifapentine,\n  * Risperidone,\n  * Ritonavir,\n  * St. John's Wort,\n  * Zidovudine\n* Hepatic function tests (SGOT, alkaline phosphatase, bilirubin) greater than 2 times the upper limit of normal or creatinine greater than 1.4 within 30 days of study entry.\n* Neurologic or psychiatric disease sufficient, in the investigator's opinion, to compromise data collection.\n* Women who are pregnant or nursing.\n* Women of childbearing potential who do not agree to use a medically recognized method of contraception during the study period.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}